TUESDAY, Feb. 12 (HealthDay News) -- For some men with prostate
cancer, hormonal therapy to beat the disease could be safely cut
from three years to half that time, a new clinical trial
When men have cancer that is confined to the prostate gland but
at high risk of worsening, one treatment option is radiation
therapy plus drugs that cut testosterone levels, because this male
hormone feeds the cancer.
Right now, doctors routinely give that hormonal therapy for two
to three years, during which time men may suffer unpleasant side
But that routine is based on a clinical trial from the 1990s
that found that adding three years of hormonal therapy to radiation
could cure certain prostate cancers. That doesn't necessarily mean
three years is ideal.
"We're still trying to figure out what duration of therapy is best," said Dr. Bruce Roth, an oncologist and professor of medicine at Washington University School of Medicine in St. Louis.
Because hormonal therapy has significant side effects -- from
erectile dysfunction and hot flashes, to drops in bone density and
muscle mass -- everyone would like the treatment period to be as
short as possible.
That's what led to the new study, which Dr. Abdenour Nabid, an
associate professor at Sherbrooke University Hospital in Canada, is
presenting Thursday at the annual Genitourinary Cancers Symposium
in Orlando, Fla. "These side effects can be huge for men," Nabid
In the study, Nabid's team randomly assigned 630 prostate cancer
patients to one of two groups. One group received radiation plus
testosterone-lowering medication for three years; the other got
hormonal therapy for just 18 months.
Overall, there were no signs that the shorter therapy put men's
lives at risk. After 6.5 years, 77 percent of the men who got three
years of hormonal therapy were still alive as were 76 percent of
those who received the 18-month regimen.
The 10-year survival rates were also nearly identical, at just
over 63 percent in both groups.
"It looks like when you get to 18 months, you reach a threshold where you are not going to improve survival by treating for a longer time," Nabid said.
Roth, who was not involved in the research, said the study might
possibly change the standard of care. But he noted that findings
presented at medical meetings are generally considered preliminary
until all the data can go through peer review prior to publication
in a journal.
Once that happens, Roth said, "I would hope that this changes
The findings described at the meeting focused on patients'
survival. Nabid said his team is still analyzing the data they
collected on side effects and quality of life.
The presumption is both would be better in the long run. Roth
said that when a man is on hormonal therapy for three years, the
chances of his testosterone levels returning to normal afterward
are low. A shorter duration of therapy boosts those odds.
Dr. Otis Brawley, chief medical officer for the American Cancer
Society, urged caution in interpreting the results of a single
study -- particularly before publication in a journal.
"I would not recommend that men choose to have 18 months of therapy based only on this study," Brawley said. However, if a man does stop at that point because he can't tolerate the side effects, this study offers some reassurance that it won't hurt his survival, he added.
In other news from the same meeting, a large study of U.S. men
found that blacks and men aged 75 and up were at relatively greater
risk of having more-aggressive tumors diagnosed through PSA
(prostate-specific antigen) screening.
In general, although the risk was still small, black men were 80
percent more likely than white men to have high-risk cancer --
those most likely to progress and threaten a man's life -- while
elderly men were over nine times more likely to have high-risk
tumors than men younger than 50.
Last year, the U.S. Preventive Services Task Force (USPSTF) came
out against routine PSA screening for men, regardless of age,
because the test often detects harmless tumors, leading to
unnecessary treatment and side effects.
But the USPSTF stance is controversial, and Roth said these new
findings highlight how complicated the issue is. He and Brawley
said the study doesn't offer any solid answers, either. For one
thing, the findings do not show whether having intermediate- or
high-risk tumors diagnosed by PSA screening actually cut men's risk
of dying from the cancer.
Brawley said he is in the camp that believes PSA screening
should be done on a very limited basis.
Roth pointed to the recommendations of the American Society of
Clinical Oncology (ASCO), which sponsored the meeting. ASCO
suggests that doctors discuss PSA screening with men likely to live
for at least 10 more years.
The reasoning is that elderly men in poor health are very
unlikely to see any benefits from PSA screening.
"I don't think we can make a blanket recommendation for all men on PSA screening," Roth said.
Learn more about prostate cancer from the
American Cancer Society.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.